Paulo Hoff
Brazil's most prominent GI oncologist, a former MD Anderson faculty member who built oncology programmes at Sírio-Libanês and ICESP.
Paulo Hoff led gastrointestinal oncology research on capecitabine and colorectal cancer at MD Anderson before returning to Brazil, where he directed the oncology centre at Hospital Sírio-Libanês and the São Paulo State Cancer Institute, and later led Oncologia D'Or.
| Title | Journal | Year |
|---|---|---|
| Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in patients with metastatic colorectal cancer | Journal of Clinical Oncology | 2001 |
Pages like this
not linked directly; found by shared links- TrialMOUNTAINEER & MOUNTAINEER-03
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialATOMIC (Alliance A021502)
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- ProductFOLFIRI (5-FU, leucovorin, irinotecan)
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- ProductCAPOX (capecitabine, oxaliplatin)
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialPARADIGM
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- PairingAnti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- TrialBREAKWATER
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
- IdeactDNA-guided adjuvant therapy as the default in stage II-III colon cancer
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.